Vizimpro
Product Images NDC 63539-197
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Vizimpro (NDC 63539-197). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by U.s. Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Vizimpro 02)
This is a chart that shows the Probability of Progression-Free Survival for two drugs, VIZIMPRO and Geftino. The numbers represent the number of patients in each group and their progression-free survival in months. The lower values on the chart indicate the number of patients at each interval. There are some censored patients in the VIZIMPRO group.*
Figure 2 (Vizimpro 03)
Logo (Vizimpro 04)
Logo (Vizimpro 05)
Principal Display Panel (15 mg Tablet Bottle Label)
This text provides storage instructions and dosage information for Vizimpro, a tablet medication containing 15 mg of dacomitinib. It instructs to store the medication between 20°C to 25°C and dispense in tight, child-resistant containers. The medication is distributed by U.S. Pharmaceuticals Piizer Inc and is made in Ireland. The text also includes a professional sample disclaimer and reference to the accompanying prescribing information. The product is not for sale and the given NDC and code are for identification purposes only.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.